Patent · US Active

Transmucosal and subcutaneous compositions

US10716786B2 · kind B2 · utility

29Cited by

105References

24Claims

0Family size

Assignee

INTRA-CELLULAR THERAPIES, INC. · US

Inventors

Peng Li · New York, US
Wei Yao · Shanghai, CN
Robert E. Davis · San Diego, US

Key dates

Filing date	Mar 23, 2018
Grant date	Jul 21, 2020
Priority date	—
Expiry date	Jan 18, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K47/38
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.